{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:25:03Z","timestamp":1740126303427,"version":"3.37.3"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.hlc.2014.12.009","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T02:17:26Z","timestamp":1419473846000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review"],"prefix":"10.1016","volume":"24","author":[{"given":"D.R.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Grenfell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2014.12.009_bib0270","article-title":"ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2014.12.009_bib0275","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","author":"Reiner \u017d","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1016\/j.hlc.2014.12.009_bib0280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0285","unstructured":"Alliance NVDP. Guidelines for the management of absolute cardiovascular risk. NHMRC Guideline Portal 2012; 2079."},{"key":"10.1016\/j.hlc.2014.12.009_bib0290","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.hlc.2014.12.009_bib0295","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hlc.2014.12.009_bib0300","doi-asserted-by":"crossref","unstructured":"Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Medical Journal of Australia 2009;191:324\u20139.","DOI":"10.5694\/j.1326-5377.2009.tb02816.x"},{"key":"10.1016\/j.hlc.2014.12.009_bib0305","doi-asserted-by":"crossref","unstructured":"National Heart Foundation of Australia. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position statement on lipid management \u2014 2005. Heart Lung and Circulation 2005;14:275\u201391.","DOI":"10.1016\/j.hlc.2005.10.010"},{"key":"10.1016\/j.hlc.2014.12.009_bib0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"29","author":"Anderson","year":"2013","journal-title":"The Canadian Journal of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2014.05.015","article-title":"Review of Clinical Practice Guidelines for the Management of LDL-Related Risk","volume":"64","author":"Morris","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0320","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/pubmed\/fdh202","article-title":"Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data","volume":"27","author":"Bhopal","year":"2005","journal-title":"Journal of Public Health"},{"key":"10.1016\/j.hlc.2014.12.009_bib0325","unstructured":"http:\/\/www.heartfoundation.org.nz\/programmes-resources\/health-professionals\/primary-prevention\/your-heart-forecast\/Your-Heart-Forecast-Online-Tool."},{"key":"10.1016\/j.hlc.2014.12.009_bib0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hlc.2014.12.009_bib0335","doi-asserted-by":"crossref","unstructured":"Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171:309\u201325. http:\/\/dx.doi.org\/10.1016\/j.ijcard.2013.11.025. Epub Nov 20.","DOI":"10.1016\/j.ijcard.2013.11.025"},{"key":"10.1016\/j.hlc.2014.12.009_bib0340","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1258\/096914106778440617","article-title":"Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes","volume":"13","author":"Marks","year":"2006","journal-title":"Journal of Medical Screening"},{"key":"10.1016\/j.hlc.2014.12.009_bib0345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1185\/03007990903494934","article-title":"Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia","volume":"26","author":"Nherera","year":"2010","journal-title":"Current Medical Research & Opinion"},{"key":"10.1016\/j.hlc.2014.12.009_bib0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MOL.0b013e32834477d2","article-title":"Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk","volume":"22","author":"Nordestgaard","year":"2011","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0355","doi-asserted-by":"crossref","unstructured":"Ray KK, Kastelein JJP, Matthijs Boekholdt S, Nicholls SJ, Khaw K-T, Ballantyne CM, et al. The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014.","DOI":"10.1093\/eurheartj\/ehu107"},{"key":"10.1016\/j.hlc.2014.12.009_bib0360","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacl.2010.03.005","article-title":"Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?","volume":"4","author":"Sniderman","year":"2010","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0365","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0370","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.amjcard.2005.10.060","article-title":"Apolipoprotein-B, Low-Density Lipoprotein Cholesterol, and the Long-Term Risk of Coronary Heart Disease in Men","volume":"97","author":"St-Pierre","year":"2006","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0375","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2337\/diacare.25.3.579","article-title":"Hypertriglyceridemic HyperapoB in Type 2 Diabetes","volume":"25","author":"Sniderman","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2014.12.009_bib0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.hlc.2014.12.009_bib0385","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2014.12.009_bib0390","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and Cardiovascular Disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0395","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress","volume":"26","author":"Koenig","year":"2006","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0400","doi-asserted-by":"crossref","unstructured":"The STABILITY Group Investigators. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine 2014;370:1702\u201311.","DOI":"10.1056\/NEJMoa1315878"},{"key":"10.1016\/j.hlc.2014.12.009_bib0405","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies\u2019 consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"Board","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2014.12.009_bib0410","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups","volume":"358","author":"Detrano","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.hlc.2014.12.009_bib0415","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0735-1097(01)01737-5","article-title":"High coronary artery calcium scores pose an extremely elevated risk for hard events","volume":"39","author":"Wayhs","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0420","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinte.164.12.1285","article-title":"Using the coronary artery calcium score to predict coronary heart disease events: A systematic review and meta-analysis","volume":"164","author":"Pletcher","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.hlc.2014.12.009_bib0425","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: New American guidelines for prevention of cardiovascular disease","volume":"382","author":"Ridker","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.hlc.2014.12.009_bib0430","doi-asserted-by":"crossref","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet; 364:937\u201352.","DOI":"10.1016\/S0140-6736(04)17018-9"},{"key":"10.1016\/j.hlc.2014.12.009_bib0435","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/hrt.2010.214858","article-title":"Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose","volume":"97","author":"Tunstall-Pedoe","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2014.12.009_bib0440","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/hrt.2007.134890","article-title":"Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study","volume":"94","author":"Hippisley-Cox","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2014.12.009_bib0445","first-page":"8","article-title":"Distribution of 10-Year and Lifetime Predicted Risks for Cardiovascular Disease in US Adults: Findings From the National Health and Nutrition Examination Survey 2003 to 2006","volume":"3","author":"Marma","year":"2010","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1016\/j.hlc.2014.12.009_bib0450","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.105.585703","article-title":"Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy: Serial Intravascular Ultrasound Observations From the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) Trial","volume":"113","author":"Schoenhagen","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2014.12.009_bib0455","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. The Lancet; 376:1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"10.1016\/j.hlc.2014.12.009_bib0460","unstructured":"Schwartz LM, S W. Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988\u20131994. Effective Clinical Practice 1999;2:76\u201385."},{"key":"10.1016\/j.hlc.2014.12.009_bib0465","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet","volume":"368","author":"Estruch","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.hlc.2014.12.009_bib0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0002-9149(84)90854-3","article-title":"Lipid research clinics coronary primary prevention trial: Results and implications","volume":"54","author":"Rifkind","year":"1984","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0475","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2014.12.009_bib0480","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0485","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"American Heart Journal"},{"key":"10.1016\/j.hlc.2014.12.009_bib0490","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. The Lancet;380:2007\u201317.","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"10.1016\/j.hlc.2014.12.009_bib0495","doi-asserted-by":"crossref","unstructured":"Pencina MJ, Navar-Boggan AM, D\u2019Agostino RB Sr, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014; 370:1422-31. http:\/\/dx.doi.org\/10.056\/NEJMoa1315665. Epub 2014 Mar 19.","DOI":"10.1056\/NEJMoa1315665"},{"key":"10.1016\/j.hlc.2014.12.009_bib0500","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1377\/hlthaff.2011.0948","article-title":"A \u2018Polypill\u2019 Aimed At Preventing Cardiovascular Disease Could Prove Highly Cost-Effective For Use In Latin America","volume":"32","author":"Bautista","year":"2013","journal-title":"Health Affairs"},{"key":"10.1016\/j.hlc.2014.12.009_bib0505","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1016\/j.hlc.2014.12.009_bib0510","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (Single-Patient) Trials for Statin-Related Myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.hlc.2014.12.009_bib0515","doi-asserted-by":"crossref","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet; 375:735\u201342.","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"10.1016\/j.hlc.2014.12.009_bib0520","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2014.12.009_bib0525","unstructured":"NICE. Lipid modification Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE guideline. 2014. http:\/\/www.nice.org.uk\/guidance\/cg181 and accessed 2\/1\/15."},{"key":"10.1016\/j.hlc.2014.12.009_bib0530","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10198-007-0043-8","article-title":"Systematic review of economic evaluations and cost analyses of guideline implementation strategies","volume":"8","author":"Vale","year":"2007","journal-title":"The European Journal of Health Economics"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950614008233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950614008233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:20:32Z","timestamp":1598613632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950614008233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1443950614008233"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2014.12.009","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2014.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}